Forget the numbers, look at the big picture - what is AMRN if they partner with PFE in the EU? Basically a holding company unless they try to develop new drugs, which will be difficult even if they acquire one. I used to own a bio that sold off the sales rights for it's two approved drugs to fund a third drug and they ended up merging with someone else out of desperation, new company is a real penny stock, currently 4 cents/shr - 3rd drug didn't pan out. Before they went after that 3rd drug they just distributed cash flow to shareholders for 2 yrs - were a holding company.